{"id":"NCT04136366","sponsor":"Aldeyra Therapeutics, Inc.","briefTitle":"The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy","officialTitle":"The GUARD Trial - Part 1: A Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard-of-Care for Prevention of Proliferative Vitreoretinopathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-15","primaryCompletion":"2022-06-14","completion":"2022-06-14","firstPosted":"2019-10-23","resultsPosted":"2025-07-09","lastUpdate":"2025-07-09"},"enrollment":106,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Proliferative Vitreoretinopathy"],"interventions":[{"type":"DRUG","name":"ADX-2191 (intravitreal methotrexate 0.8%)","otherNames":[]},{"type":"OTHER","name":"Standard surgical care procedure","otherNames":[]}],"arms":[{"label":"ADX-2191 (intravitreal methotrexate 0.8%)","type":"EXPERIMENTAL"},{"label":"Standard surgical care procedure","type":"ACTIVE_COMPARATOR"}],"summary":"The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.","primaryOutcome":{"measure":"Recurrent Retinal Detachment Compared to Historical Rates","timeFrame":"Efficacy assessment period (Week 1 to Week 24)","effectByArm":[{"arm":"ADX-2191","deltaMin":18.8,"sd":null},{"arm":"Standard Surgical Care","deltaMin":20.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":23,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":68},"commonTop":["Eye pain","Punctate keratitis","Cystoid macular oedema","Macular fibrosis","Intraocular pressure increased"]}}